Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • Harvard Bioscience's Cash from Financing Activities fell 16074.14% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.1 million, marking a year-over-year decrease of 7636.68%. This contributed to the annual value of -$131000.0 for FY2024, which is 9892.04% up from last year.
  • Harvard Bioscience's Cash from Financing Activities amounted to -$1.3 million in Q3 2025, which was down 16074.14% from -$1.3 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Cash from Financing Activities ranged from a high of $2.6 million in Q4 2021 and a low of -$4.1 million during Q4 2023
  • Its 5-year average for Cash from Financing Activities is -$1.0 million, with a median of -$1.2 million in 2025.
  • In the last 5 years, Harvard Bioscience's Cash from Financing Activities tumbled by 317765.96% in 2023 and then soared by 17650.91% in 2024.
  • Harvard Bioscience's Cash from Financing Activities (Quarter) stood at $2.6 million in 2021, then tumbled by 205.24% to -$2.7 million in 2022, then plummeted by 50.77% to -$4.1 million in 2023, then skyrocketed by 67.03% to -$1.4 million in 2024, then rose by 5.82% to -$1.3 million in 2025.
  • Its last three reported values are -$1.3 million in Q3 2025, -$1.3 million for Q2 2025, and -$1.2 million during Q1 2025.